Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00236184 · ClinicalTrials.gov registry record · Phase 3
E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
A Phase 3 study of Heartburn, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 629
- Enrollment target
- 1
- Study location
NCT00236184: Completed Phase 3 study of Heartburn, sponsored by Eisai.
NCT00236184 is a Phase 3 study of Heartburn that has completed, run by Eisai. The registered enrollment target is 629 participants, above the 350-participant average among 9 other Heartburn trials with a reported enrollment target (80% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00236184, a Phase 3 study of Heartburn, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 629 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the safety and efficacy of rabeprazole sodium 10 mg in treating frequent heartburn.
Primary Outcome
Subject was considered "complete relief" if he/she did not heartburn during the nighttime of the first dose date and no heartburn during the daytime of 1 day after the first dose date. The difference in complete relief within the first 24 hours between treatment groups was tested using a continuity corrected chi-square test without adjustment baseline heartburn severity.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG rabeprazole sodium
Study Locations (1)
California
- Jeffrey L. Newman - Vista
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 629 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
What the finished NCT00236184 record still lists
NCT00236184 is an interventional study that assigns participants to a tested intervention. The registered 629 participants enrollment target is mid-sized for trials with a published cap, above the 350-participant average among 9 other Heartburn trials with a reported enrollment target (80% higher).
The record links to 1 condition, with Heartburn appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00236184 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00236184 about?
NCT00236184 is a clinical study titled "E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers". The purpose of this study is to investigate the safety and efficacy of rabeprazole sodium 10 mg in treating frequent heartburn.
What is the current status of trial NCT00236184?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 629 participants. The study started on 2005-10. Estimated completion is 2008-06.
What conditions does trial NCT00236184 study?
This clinical trial studies the following conditions: Heartburn.
What interventions are being tested in trial NCT00236184?
The interventions under investigation include: Placebo (OTHER), rabeprazole sodium (DRUG).
Who is sponsoring clinical trial NCT00236184?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00236184 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heartburn
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00236184's enrollment target sits among peer trials
629 2nd of 9 the highest of 9 other Heartburn trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heartburn trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Domperidone in Treating Patients With Gastrointestinal Disorders
RECRUITING · Phase 3
-
Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
COMPLETED · Phase 3
-
E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
COMPLETED · Phase 3
-
Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
COMPLETED · Phase 3
-
A Study of Breath Testing for Small Intestinal Bacterial Overgrowth
RECRUITING · NA
-
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04704921 · 630 participants · Phase 2
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
- NCT04707729 · 630 participants · NA
ROX Index for the Timing of Intubation in Nasal High Flow
- NCT05061550 · 630 participants · Phase 2
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- NCT05224440 · 630 participants · NA
National Sponsorship Program for Transitioning Service Members
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia